Evidence map›Paper›PMID 30711446›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2019

Exosome-Mediated miR-29 Transfer Reduces Muscle Atrophy and Kidney Fibrosis in Mice.

Haidong Wang, Bin Wang, Aiqing Zhang, Faten Hassounah, Yiqi Seow, Matthew Wood, Fuying Ma, Janet D Klein, S Russ Price, Xiaonan H Wang

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 130 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
130citing papers in PubMed, 2 pooled it
7.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

130 citing papers in PubMed, 2 syntheses or guidelines pooled it, 195 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Nanoparticles in the Treatment of Renal Fibrosis.International journal of nanomedicine · 2026
    Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

70 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Haidong WangDepartment of Medicine, Renal Division, Emory University, Atlanta, GA 30322, USA; College of Animal Science and Veterinary Medicine, Shanxi Agricultural University, Taigu, Shanxi 030801, China.
Bin WangDepartment of Medicine, Renal Division, Emory University, Atlanta, GA 30322, USA; Institute of Nephrology, Zhong Da Hospital, Southeast University, Nanjing 210009, China.
Aiqing ZhangDepartment of Medicine, Renal Division, Emory University, Atlanta, GA 30322, USA; Department of Pediatric Nephrology, the Second Affiliated Hospital of Nanjing Medical University, Nanjing 210003, China.
Faten HassounahDepartment of Medicine, Renal Division, Emory University, Atlanta, GA 30322, USA.
Yiqi SeowMolecular Engineering Laboratory, Biomedical Medical Sciences Institutes, Singapore, Singapore; Biotechnology and Biological Sciences Research Council, United Kingdom University of Oxford, Oxford, UK.
Matthew WoodBiotechnology and Biological Sciences Research Council, United Kingdom University of Oxford, Oxford, UK.
Fuying MaDepartment of Medicine, Renal Division, Emory University, Atlanta, GA 30322, USA.
Janet D KleinDepartment of Medicine, Renal Division, Emory University, Atlanta, GA 30322, USA.
S Russ PriceDepartment of Medicine, Renal Division, Emory University, Atlanta, GA 30322, USA; Department of Biochemistry and Molecular Biology, Brody School of Medicine, East Carolina University, Greenville, NC 27834, USA.
Xiaonan H WangDepartment of Medicine, Renal Division, Emory University, Atlanta, GA 30322, USA. Electronic address: xwang03@emory.edu.
Emory University · USBiotechnology and Biological Sciences Research Council · GBSecond Affiliated Hospital of Nanjing Medical University · CNUniversity of Oxford · GB

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
MicroRNA and Muscle Wasting in UremiaR01AR060268 · NIAMS · EMORY UNIVERSITY · PI WANG, XIAONAN H · 2012 to 2016
$1.7M
Calcineurin signaling, PGC-1 alpha and protein-energy wasting in kidney diseaseR01DK095610 · NIDDK · EMORY UNIVERSITY · PI PRICE, S. RUSS · 2012 to 2015
$1.3M
Mechanisms of obesity-linked muscle atrophy and n-3 fatty acidsI01BX001456 · VA · VETERANS HEALTH ADMINISTRATION · PI PRICE, S. RUSS · 2013 to 2017
–
BLRD VA I01 BX001456NIAMS NIH HHS R01 AR060268NIDDK NIH HHS R01 DK095610NIH HHS P51 OD011132
6 · The paper itself

Abstract

Our previous study showed that miR-29 attenuates muscle wasting in chronic kidney disease. Other studies found that miR-29 has anti-fibrosis activity. We hypothesized that intramuscular injection of exosome-encapsulated miR-29 would counteract unilateral ureteral obstruction (UUO)-induced muscle wasting and renal fibrosis. We used an engineered exosome vector, which contains an exosomal membrane protein gene Lamp2b that was fused with the targeting peptide RVG (rabies viral glycoprotein peptide). RVG directs exosomes to organs that express the acetylcholine receptor, such as kidney. The intervention of Exo/miR29 increased muscle cross-sectional area and decreased UUO-induced upregulation of TRIM63/MuRF1 and FBXO32/atrogin-1. Interestingly, renal fibrosis was partially depressed in the UUO mice with intramuscular injection of Exo/miR29. This was confirmed by decreased TGF-β, alpha-smooth muscle actin, fibronectin, and collagen 1A1 in the kidney of UUO mice. When we used fluorescently labeled Exo/miR29 to trace the Exo/miR route in vivo and found that fluorescence was visible in un-injected muscle and in kidneys. We found that miR-29 directly inhibits YY1 and TGF-β3, which provided a possible mechanism for inhibition of muscle atrophy and renal fibrosis by Exo/miR29. We conclude that Exo/miR29 ameliorates skeletal muscle atrophy and attenuates kidney fibrosis by downregulating YY1 and TGF-β pathway proteins.

Indexed as

AnimalsEpithelial-Mesenchymal TransitionExosomesFibronectinsFibrosisKidney DiseasesMiceMice, Inbred C57BLMicroRNAsMuscular AtrophySignal TransductionTransforming Growth Factor beta1Transforming Growth Factor beta3FibronectinsMicroRNAsMIRN29 microRNA, mouseTransforming Growth Factor beta1Transforming Growth Factor beta3FBXO32/atrogin-1TGF-β1TGF-β3TRIM63/MuRF1Yin Yang 1α-SMA

Identifiers

PMID30711446
PMCPMC6403486
OpenAlexW2911048719

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.